Siegfried breaks ground on new global R&D Center for Drug Substances in Evionnaz

Siegfried will create a new global R&D Center in Evionnaz, investing CHF 25 million to boost capacity, drive growth, and leading to the creation of over 100 skilled jobs.

Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO), has officially broken ground on its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz. The facility, set to begin operations in 2024, will work in tandem with the R&D Center in Zofingen to substantially increase Siegfried’s R&D capacity and drive future growth.

The company will invest up to CHF 25 million in the new R&D Center, where over 100 highly skilled specialists will collaborate with Siegfried’s customers to bring innovative products to an industrial scale. The center will feature advanced chemical and analytical facilities, state-of-the-art laboratories, and offer chemical process R&D and analytical development services for the entire Drug Substances network. This project reaffirms Siegfried’s commitment to its Evionnaz site as a crucial component within its global Drug Substances network.

Siegfried selected the canton of Valais as the location for its new global R&D Center due to its strategic importance within the company’s network and its long-standing presence in the region. Valais provides an ideal setting for the R&D Center, with its strong reputation in the life sciences industry, skilled workforce, and proximity to renowned research institutions. The location also benefits from the region’s infrastructure and accessibility, enabling efficient collaboration and exchange with Siegfried’s global partners and clients.

A significant milestone for Siegfried’s growth strategy

Wolfgang Wienand, CEO of Siegfried, emphasized the importance of the new R&D Center in Evionnaz for the company’s global network and its dedication to providing advanced research and development services to its customers. He stated that the center represents a significant milestone in Siegfried’s growth strategy and a considerable step towards becoming a leader in the CDMO space.

Siegfried specializes in manufacturing pharmaceutical active pharmaceutical ingredients (APIs) and their intermediates, as well as drug products such as tablets, capsules, sterile vials, ampoules, cartridges, and ointments for the pharmaceutical industry. In 2022, the company reported sales of CHF 1.229 billion and employed more than 3,600 people across eleven sites on three continents.